SEARCH:   Advanced

Blood, 1 January 2007, Vol. 109, No. 1, pp. 58-60. Prepublished online as a Blood First Edition Paper on September 14, 2006; DOI 10.1182/blood-2006-03-011239. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-03-011239v1 109/1/58    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Rousselot, P. Articles by Mahon, F.-X. Search for Related Content PubMed PubMed Citation Articles by Rousselot, P. Articles by Mahon, F.-X. Related Collections Neoplasia Oncogenes and Tumor Suppressors Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief report Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years Philippe Rousselot1,2, Francoise Huguet3, Delphine Rea1, Laurence Legros4, Jean Michel Cayuela5, Odile Maarek5, Odile Blanchet6, Gerald Marit7, Eliane Gluckman1, Josy Reiffers8, Martine Gardembas9, François-Xavier Mahon10,, The Intergroupe Français des Leucémies Myéloïdes Chronique (FILMC) 1 Fédération d'hématologie et Centre d'Investigation Clinique, Hôpital Saint-Louis, Paris, France; 2 Service d'Hématologie et d'Oncologie, Hôpital Mignot, Versailles, France; 3 Service d'Hématologie, Hôpital de Purpan, Toulouse, France; 4 Service d'hématologie, Hôpital Larchet, Nice, France; 5 Laboratoire Central d'Hématologie, Institut National de la Santé et de la Recherche Médicale (INSERM) Unité (U) 728, Hôpital Saint-Louis, Paris, France; 6 Laboratoire d'hématologie, Centre Hospitalo-Universitaire (CHU) d'Angers, France; 7 Service des Maladies du Sang, CHU du Haut Lévèque, Pessac, France; 8 Institut Bergonié, Bordeaux, France; 9 Service d'Hématologie, CHU d'Angers, France; 10 Laboratoire Hématopoïèse normale et leucemique, Université Victor Ségalen Bordeaux 2, INSERM E217, France In the present study, we address the issue of the discontinuation of imatinib mesylate (Gleevec) in chronic myelogenous leukemia with undetectable residual disease for more than 2 years. Twelve patients were included. The median duration of real-time quantitative–polymerase chain reaction (RTQ-PCR) negativity and imatinib therapy were, respectively, 32 months (range, 24-46 months) and 45 months (range, 32-56 months) before imatinib interruption. Six patients displayed a molecular relapse with a detectable BCR-ABL transcript at 1, 1, 2, 3, 4, and 5 months. Imatinib was then reintroduced and led to a novel molecular response in most patients. Six other patients (50%) still have an undetectable level of BCR-ABL transcript after a median follow-up of 18 months (range, 9-24 months). We hypothesize that relapses observed within 6 months reflect the kinetics of undetectable dividing chronic myelogenous leukemia (CML) cells. Those cells may be eradicated or controlled in long-term nonrelapsing patients, as described in our study. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. A. Sipkins Rendering the Leukemia Cell Susceptible to Attack N. Engl. J. Med., September 24, 2009; 361(13): 1307 - 1309. [Full Text] [PDF] E. Mattarucchi, O. Spinelli, A. Rambaldi, F. Pasquali, F. Lo Curto, L. Campiotti, and G. Porta Molecular Monitoring of Residual Disease in Chronic Myeloid Leukemia by Genomic DNA Compared with Conventional mRNA Analysis J. Mol. Diagn., September 1, 2009; 11(5): 482 - 487. [Abstract] [Full Text] [PDF] M. Baccarani, M. Dreyling, and On behalf of the ESMO Guidelines Working Group Chronic myelogenous leukemia: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv105 - iv107. [Full Text] [PDF] A. Hayat, S. R. McCann, S. Langabeer, S. Irvine, M. F. McMullin, and E. Conneally Effective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation Haematologica, February 1, 2009; 94(2): 296 - 298. [Full Text] [PDF] J. M. Goldman Chronic Myeloid Leukemia Stem Cells: Now on the Run J. Clin. Oncol., January 10, 2009; 27(2): 313 - 314. [Full Text] [PDF] T. O'Hare and M. W. Deininger Toward a Cure For Chronic Myeloid Leukemia Clin. Cancer Res., December 15, 2008; 14(24): 7971 - 7974. [Full Text] [PDF] H. Konig, M. Copland, S. Chu, R. Jove, T. L. Holyoake, and R. Bhatia Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells Cancer Res., December 1, 2008; 68(23): 9624 - 9633. [Abstract] [Full Text] [PDF] H.-J. Kolb Graft-versus-leukemia effects of transplantation and donor lymphocytes Blood, December 1, 2008; 112(12): 4371 - 4383. [Abstract] [Full Text] [PDF] D. Marin, D. Milojkovic, E. Olavarria, J. S. Khorashad, H. de Lavallade, A. G. Reid, L. Foroni, K. Rezvani, M. Bua, F. Dazzi, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor Blood, December 1, 2008; 112(12): 4437 - 4444. [Abstract] [Full Text] [PDF] F.-X. Mahon, F. Huguet, F. Guilhot, L. Legros, F. E Nicolini, A. Charbonnier, A. Guerci, D. Rea, B. R. Varet, M. Gardembas, et al. Is It Possible to Stop Imatinib in Patients with Chronic Myeloid Leukemia? An Update from a French Pilot Study and First Results from the Multicentre << Stop Imatinib >> (STIM) Study Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 187 - 187. [Abstract] J. E. Cortes Imatinib Therapy for Chronic Myeloid Leukemia: Where Do We Go Now? J. Clin. Oncol., July 10, 2008; 26(20): 3308 - 3309. [Full Text] [PDF] S. M. Pye, J. Cortes, P. Ault, A. Hatfield, H. Kantarjian, R. Pilot, G. Rosti, and J. F. Apperley The effects of imatinib on pregnancy outcome Blood, June 15, 2008; 111(12): 5505 - 5508. [Abstract] [Full Text] [PDF] M. Baccarani, F. Pane, and G. Saglio Monitoring treatment of chronic myeloid leukemia Haematologica, February 1, 2008; 93(2): 161 - 169. [Full Text] [PDF] M. W.N. Deininger Imatinib Resistance and the Difficulty of Eradicating Leukemia Stem Cells ASCO Educational Book, January 1, 2008; 2008(1): 318 - 323. [Abstract] [Full Text] [PDF] S. Branford, J. F. Seymour, A. Grigg, C. Arthur, Z. Rudzki, K. Lynch, and T. Hughes BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria Clin. Cancer Res., December 1, 2007; 13(23): 7080 - 7085. [Abstract] [Full Text] [PDF] A. D. Klion, J. Robyn, I. Maric, W. Fu, L. Schmid, S. Lemery, P. Noel, M. A. Law, M. Hartsell, C. Talar-Williams, et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing Blood, November 15, 2007; 110(10): 3552 - 3556. [Abstract] [Full Text] [PDF] J. M. Goldman How I treat chronic myeloid leukemia in the imatinib era Blood, October 15, 2007; 110(8): 2828 - 2837. [Abstract] [Full Text] [PDF] C. A. Schiffer BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia N. Engl. J. Med., July 19, 2007; 357(3): 258 - 265. [Full Text] [PDF] S. Branford Chronic Myeloid Leukemia: Molecular Monitoring in Clinical Practice Hematology, January 1, 2007; 2007(1): 376 - 383. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020